PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada. DrugSorb-ATR is an FDA-designated Breakthrough Device designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting ...

PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device, (the denial letter). DrugSo ...

1 | Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 19 ...

The Unrecognized Faces of Critical Illness CytoSorbents Corporation Q3 2023 Earnings Conference Call November 9, 2023 Conference Call Participants Moderator: Taylor Devlin CytoSorbents Corporation Phillip Chan, MD, PhD Chief Executive Officer Vincent Capponi, MS President and Chief Operating Officer Efthymios "Makis" Deliargyris MD, FACC, FESC, FSCAI Chief Medical Officer 2 Kathleen Bloch, MBA, CPA Chief Financial Officer Christian Steiner, MD Executive VP Sales & Marketing Managing Director CytoSorbents Eu ...

The Unrecognized Faces of Critical Illness CytoSorbents Corporation Q4 2023 and FY 2023 Earnings Conference Call March 14, 2024 Conference Call Participants Moderator: Taylor Devlin CytoSorbents Corporation Phillip Chan, MD, PhD Chief Executive Officer Vincent Capponi, MS President and Chief Operating Officer Efthymios "Makis" Deliargyris MD, FACC, FESC, FSCAI Chief Medical Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Christian Steiner, MD Executive VP Sales & Marketing Managing Director CytoSor ...

The Unrecognized Faces of Critical Illness CytoSorbents Corporation Nasdaq: CTSO Q1 2024 Earnings Conference Call May 9, 2024 Conference Call Participants Moderator: Eric Ribner LifeSci Advisors Christian Steiner, MD Executive VP Sales & Marketing Managing Director CytoSorbents Europe GmbH Phillip Chan, MD, PhD Chief Executive Officer Vincent Capponi, MS President and Chief Operating Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Efthymios "Makis" Deliargyris MD, FACC, FESC, FSCAI Chief Medical Of ...

The Unrecognized Faces of Critical Illness CytoSorbents Corporation Nasdaq: CTSO Q2 2024 Earnings Conference Call August 13, 2024 Conference Call Participants Moderator: Eric Ribner LifeSci Advisors Christian Steiner, MD Executive VP Sales & Marketing Managing Director CytoSorbents Europe GmbH Christopher Cramer, MS, MBA Senior VP Business Development 2 Phillip Chan, MD, PhD Chief Executive Officer Vincent Capponi, MS President and Chief Operating Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Eft ...

The Emergence of CytoSorbents Corporation Nasdaq: CTSO Q3 2024 Earnings Conference Call November 7, 2024 DrugSorb-ATR is an investigational device currently under U.S. FDA and Health Canada review. It is not yet approved or cleared in any country. Conference Call Participants Moderator: Adanna Alexander, PhD ICR Healthcare Efthymios "Makis" Deliargyris MD, FACC, FESC, FSCAI Chief Medical Officer Christopher Cramer, MS, MBA Senior VP Business Development 2 Phillip Chan, MD, PhD Chief Executive Officer Vincen ...

CytoSorbents Corporation Nasdaq: CTSO Q1 2025 Financial Results and Recent Business Highlights Conference Call May 14, 2025 Conference Call Participants Phillip Chan, MD, PhD Chief Executive Officer Moderator: Adanna Alexander, PhD VP Investor Relations, ICR Healthcare Efthymios "Makis" Deliargyris MD, FACC, FESC, FSCAI Chief Medical Officer Peter J. Mariani, CPA Chief Financial Officer 2 Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries ...

Cytosorbents (CTSO) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Alright. Good morning, everyone. My name is Mike Sarcone. I'm an analyst on the US medical supplies and devices team, and this is day two of the Jefferies twenty twenty five New York Health Care Conference. This is a session with CytoSorbents. And from the company, we've got CEO Phil Chan and CFO Pete Mariani. Gentlemen, thank you for joining us. And Phil is actually going to kick it off with some prepared commentary, and then we'll get ...